Patents Assigned to NeuralStem Biopharmaceuticals, Ltd.
  • Publication number: 20090263901
    Abstract: A systematic and efficient method for establishing stable neural stem cell lines and neuronal progenitor lines is described. The resulting cell lines provide robust, simple, and reproducible cultures of human and other mammalian neurons in commercially useful mass quantities while maintaining normal karyotypes and normal neuronal phenotypes.
    Type: Application
    Filed: April 15, 2009
    Publication date: October 22, 2009
    Applicant: NeuralStem Biopharmaceuticals, Ltd.
    Inventors: Renji Yang, Karl K. Johe
  • Patent number: 7544511
    Abstract: A systematic and efficient method for establishing stable neural stem cell lines and neuronal progenitor lines is described. The resulting cell lines provide robust, simple, and reproducible cultures of human and other mammalian neurons in commercially useful mass quantities while maintaining normal karyotypes and normal neuronal phenotypes.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: June 9, 2009
    Assignee: Neuralstem Biopharmaceuticals Ltd.
    Inventors: Renji Yang, Karl K. Johe
  • Patent number: 6284539
    Abstract: The present invention describes a novel method to direct a particular set of fate choice decisions by multipotential precursor cells from the central nervous system. Specifically we show that introducing the gene coding for the nuclear receptor, Nurr1, into central nervous system (CNS) stem cells causes cells to adopt a dopaminergic cell fate. One use of this technology would be to prepare in vitro neural populations enriched in dopaminergic cells for transplantation in Parkinson's Disease or other neurological disorders. Furthermore, the finding that Nurr1 expression induces a dopaminergic phenotype suggests that introducing this gene into the brains of patients in which dopaminergic cells are degenerating or have been injured may promote the functional recovery of these neurons and thus the clinical recovery of the patient. Finally, the technology described in this application could be incorporated into a program of drug screening or gene discovery.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: September 4, 2001
    Assignee: NeuralStem Biopharmaceuticals, Ltd.
    Inventors: David C. Bowen, Karl K. Johe
  • Patent number: 6040180
    Abstract: The present invention reveals in vitro cultures of region-specific, terminally differentiated, mature neurons derived from cultures of mammalian multipotential CNS stem cells and an in vitro procedure by which the differentiated neurons may be generated. The procedure involves the culturing of multipotential CNS stem cells from a specific region in a chemically defined serum-free culture medium containing a growth factor; replacing the medium with growth factor-free medium; harvesting the stem cells by trypsinization; plating the stem cells at a density of between 100,000 to 250,000 cells per square centimeter; and culturing the stem cells in a glutamic acid-free chemically defined serum-free culture medium.
    Type: Grant
    Filed: May 7, 1997
    Date of Patent: March 21, 2000
    Assignee: NeuralStem Biopharmaceuticals, Ltd.
    Inventor: Karl K. Johe